Automated Biochemistry Analyzers Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 – The Daily Chronicle

The Global Automated Biochemistry Analyzers Market analysis report published on Upmarketresearch.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://www.upmarketresearch.com/home/requested_sample/75878

The Global Automated Biochemistry Analyzers Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Automated Biochemistry Analyzers Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Automated Biochemistry Analyzers Market Report: https://www.upmarketresearch.com/home/enquiry_before_buying/75878

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Automated Biochemistry Analyzers Market as:Global Automated Biochemistry Analyzers Market Size & Share, by Regions

Global Automated Biochemistry Analyzers Market Size & Share, by ProductsStationary Biochemistry AnalyzersPortable Biochemistry Analyzers

Global Automated Biochemistry Analyzers Market Size & Share, ApplicationsHospital and Diagnostic LaboratoriesHome Care and AcademicResearch Institutes

Key PlayersAbbottDanaherHitachiRocheSiemensThermo Fisher Scientific

Avail the Discount on this Report @ https://www.upmarketresearch.com/home/request_for_discount/75878

UpMarketResearch offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About UpMarketResearch:UpMarketResearch (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

Read more:
Automated Biochemistry Analyzers Market Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2025 - The Daily Chronicle

Innovative Supplement Brand Seeks Applicants For Nutritional Research Including Blood Biochemistry Assessment – Plant Based News

Heights' Smart Supplement was designed as a premium-quality replacement for most common supplements and multivitamins(Photo: Emma Inwood)

An innovative plant-based supplements brand is looking for five people to take part in nutritional research which aims to demonstrate that its supplement can improve biochemical markers of nutrition over three months.

Heights counts Stephen Fry, the founders of the biggest European plant-based companies like Allplants and THIS, Dr. Rangan Chatterjee, influencer Zanna Van Dijk, plant-based brand Vevolution, and Rene Elliott, founder of Planet Organic, among its customers and vocal fans.

The companys flagship Smart Supplement - which was designed as a premium-quality replacement for most common supplements and multivitamins - combines 19 essential healthy fats, antioxidants, vitamins, and minerals in the quantities shown to have the highest impact on the health of your brain and body, in a formulation you can actually absorb.

Its nutrient highlights include antioxidants, which are great for counterbalancing the effects of environmental pollutants and other lifestyle factors that put stress on our bodies. Heights contains five powerful antioxidants; vitamin E, anthocyanins, zinc, selenium and Vitamin C.

The supplement also features Omega 3 oil (DHA and EPA from algae oil). For those that don't already know, Omega 3 Oil optimises the structure of your brain and can help with mood and mood disorders. DHA can also improve memory and focus, and EPA helps to fight cellular inflammation.

B vitamins - which provide your cells with energy and support the efficient transport of information through your brain - are included, alongside Vitamin D, which has been government-recommended during lockdown, and is extra-important as we slide into the autumn and winter months. Deficiency is common and is associated with poor immune function and many other health problems including depression.

Unlike pretty much any multivitamin in the market, Heights uses a patented 'clever capsule', which not only slow releases the nutrients into your gut but enables them to encapsulate Omega 3 oil too.

Heights uses a patented 'clever capsule' (Photo: Emma Inwood)

Heights is carrying out its trial to demonstrate that Heights is improving biochemical markers of nutrition over three months. It will recruit six volunteers who are readers of Plant Based News, who follow a plant-based diet, and ideally havent taken any vitamins for three months

Discussing what kind of results it is hoping to see in vegan participants, the company said: While we know that a vegan diet can be nutritionally complete, we also know that nutritional deficiencies are more common in the vegan community. Most guidelines recommend vegans to supplement with B vitamins and vitamin D but supplementation with algae oil is still not commonplace.

Wed love to see improvements to biomarkers of vitamin status and omega 3 profile and were also hopeful of being able to measure improvements in mental wellbeing and performance in both the vegan and omnivore groups.

It added that while a plant-based diet can reduce exposure to some of the risk factors for poor brain health, a lower intake of B vitamins and inadequate conversion of plant-based omega 3 into DHA can mean that brain health in vegans is reduced.

Complaints such as brain fog, challenges with mental focus, mood, sleep and memory are commonly cited reasons for vegans returning to an omnivorous diet, said Heights. By promoting the importance of brain health and appropriate supplementation within the vegan community, we can support more people to thrive on a vegan diet and maintain their principals as well as their health."

To take part in the trial, applicants must be plant-based, and not take supplements*, and be able to attend appointments on Londons Harley Street. Compliance with supplementation is important and Heights would like participants to achieve 80-90 percent compliance with their supplement. The company will be in touch through the trial to support participants with this, and will offer tips on how to maximise compliance.

The successful applicants will be invited to collaborate with leading Harley Street scientists and dietitians, to see first hand the impact of optimum nutrition on your brain health and mental well-being.

They will be offered:

The competition closes on Monday, September 7. Participants must be aged 18 or older and be able to attend appointments on Harley Street, London. Full T&Cs are available at yourheights.com.

*Those taking regular medication are advised to speak to their doctor before taking new supplements.

**This is a paid-for advertorial.

Read more:
Innovative Supplement Brand Seeks Applicants For Nutritional Research Including Blood Biochemistry Assessment - Plant Based News

Automated Biochemistry Analyzers Market Analysis by Application, Types, Region and Business Growth Drivers by 2026 – Scientect

Market Study Report, LLC, has recently added a report on the Automated Biochemistry Analyzers market which provides a holistic synopsis of the market size, market valuation, revenue estimate, SWOT analysis, and the geographical spectrum of this industry. The report accurately underlines the key challenges and opportunities for growth during the forecast period. In addition, it sheds light on the current competitive scenario and reviews the business strategies adopted by the Automated Biochemistry Analyzers market players.

The research report on Automated Biochemistry Analyzers market provides an in-depth assessment of the production and consumption patterns of this business sphere. The document elaborates on major aspects concerning the production, such as manufacturing patterns of the products, revenue share, and impact on gross margins.

Request a sample Report of Automated Biochemistry Analyzers Market at:https://www.marketstudyreport.com/request-a-sample/2886807

Further, it encompasses the consumption patterns, providing a brief overview of the measure of consumption value and volume of all products, import & export settings, and associated sales prices across the regions. In addition, the study highlights the production and consumption forecast in the view of the COVID-19 pandemic.

A summary of the regional scope:

Overview of the product landscape:

A gist of the application spectrum:

Ask for Discount on Automated Biochemistry Analyzers Market Report at:https://www.marketstudyreport.com/check-for-discount/2886807

An overview of the competitive landscape of the Automated Biochemistry Analyzers market:

Comprehensive assessment of all opportunities and risks in the Automated Biochemistry Analyzers market.

This exclusive study addresses key questions for stakeholders in the Automated Biochemistry Analyzers Market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-automated-biochemistry-analyzers-market-research-report-2020-market-size-competitive-landscape-regional-outlook-and-covid-19-impact-analysis

Related Reports:

1. Global Industrial Inertial Systems Market Research Report 2020, Market Size, Competitive Landscape, Regional Outlook and COVID-19 Impact AnalysisRead More: https://www.marketstudyreport.com/reports/global-industrial-inertial-systems-market-research-report-2020-market-size-competitive-landscape-regional-outlook-and-covid-19-impact-analysis

2. Global Industrial Air Pollution Control Solutions Market Research Report 2020, Market Size, Competitive Landscape, Regional Outlook and COVID-19 Impact AnalysisRead More: https://www.marketstudyreport.com/reports/global-industrial-air-pollution-control-solutions-market-research-report-2020-market-size-competitive-landscape-regional-outlook-and-covid-19-impact-analysis

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Continued here:
Automated Biochemistry Analyzers Market Analysis by Application, Types, Region and Business Growth Drivers by 2026 - Scientect

Research To Advance Crop Resilience – Texas A&M Today – Texas A&M University Today

Junqi Song, Texas A&M AgriLife Research assistant professor.

Texas A&M AgriLife

A multi-institution, international study led byTexas A&M AgriLife Researchwill investigate how a process that triggers DNA repair in plants also plays a role in strengthening their disease immunity.

Understanding key functions of the process, which is well-studied in humans, will help scientists design better disease-control strategies for highly resilient food crops, said Junqi Song, AgriLife Research assistant professor of plant pathology in Dallas. Song leads the $1.1 millionNational Science Foundationgrant project alongsidePing He, Texas A&M University Presidential Impact Fellow and professor of biochemistry and biophysics, Bryan-College Station.

When invading pathogens infect plants, the enzyme poly(ADP-ribose) polymerase attaches the molecule poly(ADP-ribose), or PAR, to certain proteins. This process is PARylation, and it activates a number of responses to pathogens, including DNA repair, immune responses and cell death, among others.

Ping He, Texas A&M Presidential Impact Fellow and professor of biochemistry and biophysics.

Texas A&M AgriLife

We are most interested in the link between DNA repair and immune responses, He said. We know a lot about how they function individually. But new evidence suggests that PARylation could be a mechanical link between them.

This is the crux of their research, and it is most likely applicable to all crop plants. Among crops, Song said, PARylation and plant immune response are genetically well conserved, or largely universal.

PARylation has been studied extensively in humans, due to its profound medical impact on many inflammatory and malignant disorders, namely cancer and related chemotherapy, he said.

But the function of PARylation in plants is poorly understood, Song said.

Over the next two years, Song and He along with collaborators at academic and research institutions across the globe aim to identify how PARylation targets immunity genes and proteins. By determining the intricately connected functions of DNA repair and immune responses, they will gain insight into how PARylation protects DNA from pathogen damage throughout an entire plant.

The work of this multilateral project will provide insights that can signal a big next step in resilient crop production that is sustainable into the future, Song said.

The work dovetails with AgriLife Researchs overarching push to meet demands of a changing climate, and to be able to grow crops sustainably in increasingly harsher conditions, especially in urban and suburban settings.

The push includes a new urban research center in Dallas. The center houses Songs lab and focuses on growing food in cities, preserving important water and land resources, as well as enhancing human health. Thegenomics program at the Dallas Center, led by Qingyi Yu, professor of plant genomics, is also collaborating on the PARylation research project.

Other collaborators are the University of Texas Southwestern Medical School, The University of Wisconsin-Madison and researchers from a number of national and international academic and scientific research institutions.

See the original post here:
Research To Advance Crop Resilience - Texas A&M Today - Texas A&M University Today

Biochemical Pesticides Market Progresses for Huge Profits by 2027 with demanding Key Players like Certis USA, BASF, Bayer, Isagro, Marrone Bio…

Overview Of Biochemical Pesticides Industry 2020-2027:

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The Biochemical Pesticides Market analysis summary by Reports Insights is a thorough study of the current trends leading to this vertical trend in various regions. Research summarizes important details related to market share, market size, applications, statistics and sales. In addition, this study emphasizes thorough competition analysis on market prospects, especially growth strategies that market experts claim.

Biochemical Pesticides Market competition by top manufacturers as follow: , Valent BioSciences, Certis USA, BASF, Bayer, Isagro, Marrone Bio Innovations, Neudorff, Bioworks, Koppert

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/128347

The global Biochemical Pesticides market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

The Type Coverage in the Market are: LiquidPowder

Market Segment by Applications, covers:Insect ControlWeed ControlPlant Disease ControlOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Major factors covered in the report:

To get this report at a profitable rate.: https://reportsinsights.com/discount/128347

The analysis objectives of the report are:

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Biochemical-Pesticides-Market-128347

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

More:
Biochemical Pesticides Market Progresses for Huge Profits by 2027 with demanding Key Players like Certis USA, BASF, Bayer, Isagro, Marrone Bio...

Dibutyl Itaconate (CAS 2155-60-4) Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 |…

Dibutyl Itaconate (CAS 2155-60-4) Market Research Report

LOS ANGELES, United States: The report is an all-inclusive research study of the global Dibutyl Itaconate (CAS 2155-60-4) market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Dibutyl Itaconate (CAS 2155-60-4) market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Dibutyl Itaconate (CAS 2155-60-4) report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2118684/global-dibutyl-itaconate-cas-2155-60-4-market

In addition, market revenues based on region and country are provided in the Dibutyl Itaconate (CAS 2155-60-4) report. The authors of the report have also shed light on the common business tactics adopted by players. The leading players of the global Dibutyl Itaconate (CAS 2155-60-4) market and their complete profiles are included in the report. Besides that, investment opportunities, recommendations, and trends that are trending at present in the global Dibutyl Itaconate (CAS 2155-60-4) market are mapped by the report. With the help of this report, the key players of the global Dibutyl Itaconate (CAS 2155-60-4) market will be able to make sound decisions and plan their strategies accordingly to stay ahead of the curve.

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Dibutyl Itaconate (CAS 2155-60-4) market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Dibutyl Itaconate (CAS 2155-60-4) market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

Key Players Mentioned in the Global Dibutyl Itaconate (CAS 2155-60-4) Market Research Report: Zhejiang Guoguang Biochemistry Co.,Ltd, Hangzhou Hairui Chemical Co., Ltd., Hanke Chemical, Qingdao Kehai Bio

Global Dibutyl Itaconate (CAS 2155-60-4) Market Segmentation by Product: 96% Ester Content>96% Ester Content

Global Dibutyl Itaconate (CAS 2155-60-4) Market Segmentation by Application: Organic SynthesisPlasticizerOther

The Dibutyl Itaconate (CAS 2155-60-4) Market report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Dibutyl Itaconate (CAS 2155-60-4) market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Dibutyl Itaconate (CAS 2155-60-4) market and its potential to grow in the years to come.

Key questions answered in the report:

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2118684/global-dibutyl-itaconate-cas-2155-60-4-market

Table of Contents:

1 Study Coverage1.1 Dibutyl Itaconate (CAS 2155-60-4) Product Introduction1.2 Market Segments1.3 Key Dibutyl Itaconate (CAS 2155-60-4) Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size Growth Rate by Type1.4.2 96% Ester Content1.4.3 >96% Ester Content1.5 Market by Application1.5.1 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size Growth Rate by Application1.5.2 Organic Synthesis1.5.3 Plasticizer1.5.4 Other1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size, Estimates and Forecasts2.1.1 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue 2015-20262.1.2 Global Dibutyl Itaconate (CAS 2155-60-4) Sales 2015-20262.2 Global Dibutyl Itaconate (CAS 2155-60-4), Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Dibutyl Itaconate (CAS 2155-60-4) Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Dibutyl Itaconate (CAS 2155-60-4) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Dibutyl Itaconate (CAS 2155-60-4) Competitor Landscape by Players3.1 Dibutyl Itaconate (CAS 2155-60-4) Sales by Manufacturers3.1.1 Dibutyl Itaconate (CAS 2155-60-4) Sales by Manufacturers (2015-2020)3.1.2 Dibutyl Itaconate (CAS 2155-60-4) Sales Market Share by Manufacturers (2015-2020)3.2 Dibutyl Itaconate (CAS 2155-60-4) Revenue by Manufacturers3.2.1 Dibutyl Itaconate (CAS 2155-60-4) Revenue by Manufacturers (2015-2020)3.2.2 Dibutyl Itaconate (CAS 2155-60-4) Revenue Share by Manufacturers (2015-2020)3.2.3 Global Dibutyl Itaconate (CAS 2155-60-4) Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Dibutyl Itaconate (CAS 2155-60-4) Revenue in 20193.2.5 Global Dibutyl Itaconate (CAS 2155-60-4) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Dibutyl Itaconate (CAS 2155-60-4) Price by Manufacturers3.4 Dibutyl Itaconate (CAS 2155-60-4) Manufacturing Base Distribution, Product Types3.4.1 Dibutyl Itaconate (CAS 2155-60-4) Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Dibutyl Itaconate (CAS 2155-60-4) Product Type3.4.3 Date of International Manufacturers Enter into Dibutyl Itaconate (CAS 2155-60-4) Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size by Type (2015-2020)4.1.1 Global Dibutyl Itaconate (CAS 2155-60-4) Sales by Type (2015-2020)4.1.2 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue by Type (2015-2020)4.1.3 Dibutyl Itaconate (CAS 2155-60-4) Average Selling Price (ASP) by Type (2015-2026)4.2 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Type (2021-2026)4.2.1 Global Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast by Type (2021-2026)4.2.2 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast by Type (2021-2026)4.2.3 Dibutyl Itaconate (CAS 2155-60-4) Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Dibutyl Itaconate (CAS 2155-60-4) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Dibutyl Itaconate (CAS 2155-60-4) Market Size by Application (2015-2020)5.1.1 Global Dibutyl Itaconate (CAS 2155-60-4) Sales by Application (2015-2020)5.1.2 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue by Application (2015-2020)5.1.3 Dibutyl Itaconate (CAS 2155-60-4) Price by Application (2015-2020)5.2 Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Application (2021-2026)5.2.1 Global Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast by Application (2021-2026)5.2.2 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast by Application (2021-2026)5.2.3 Global Dibutyl Itaconate (CAS 2155-60-4) Price Forecast by Application (2021-2026)

6 North America6.1 North America Dibutyl Itaconate (CAS 2155-60-4) by Country6.1.1 North America Dibutyl Itaconate (CAS 2155-60-4) Sales by Country6.1.2 North America Dibutyl Itaconate (CAS 2155-60-4) Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Type6.3 North America Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Application

7 Europe7.1 Europe Dibutyl Itaconate (CAS 2155-60-4) by Country7.1.1 Europe Dibutyl Itaconate (CAS 2155-60-4) Sales by Country7.1.2 Europe Dibutyl Itaconate (CAS 2155-60-4) Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Type7.3 Europe Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Application

8 Asia Pacific8.1 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) by Region8.1.1 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) Sales by Region8.1.2 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Type8.3 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Application

9 Latin America9.1 Latin America Dibutyl Itaconate (CAS 2155-60-4) by Country9.1.1 Latin America Dibutyl Itaconate (CAS 2155-60-4) Sales by Country9.1.2 Latin America Dibutyl Itaconate (CAS 2155-60-4) Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Type9.3 Central & South America Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Application

10 Middle East and Africa10.1 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) by Country10.1.1 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) Sales by Country10.1.2 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Type10.3 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) Market Facts & Figures by Application

11 Company Profiles11.1 Zhejiang Guoguang Biochemistry Co.,Ltd11.1.1 Zhejiang Guoguang Biochemistry Co.,Ltd Corporation Information11.1.2 Zhejiang Guoguang Biochemistry Co.,Ltd Description and Business Overview11.1.3 Zhejiang Guoguang Biochemistry Co.,Ltd Sales, Revenue and Gross Margin (2015-2020)11.1.4 Zhejiang Guoguang Biochemistry Co.,Ltd Dibutyl Itaconate (CAS 2155-60-4) Products Offered11.1.5 Zhejiang Guoguang Biochemistry Co.,Ltd Related Developments11.2 Hangzhou Hairui Chemical Co., Ltd.11.2.1 Hangzhou Hairui Chemical Co., Ltd. Corporation Information11.2.2 Hangzhou Hairui Chemical Co., Ltd. Description and Business Overview11.2.3 Hangzhou Hairui Chemical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.2.4 Hangzhou Hairui Chemical Co., Ltd. Dibutyl Itaconate (CAS 2155-60-4) Products Offered11.2.5 Hangzhou Hairui Chemical Co., Ltd. Related Developments11.3 Hanke Chemical11.3.1 Hanke Chemical Corporation Information11.3.2 Hanke Chemical Description and Business Overview11.3.3 Hanke Chemical Sales, Revenue and Gross Margin (2015-2020)11.3.4 Hanke Chemical Dibutyl Itaconate (CAS 2155-60-4) Products Offered11.3.5 Hanke Chemical Related Developments11.4 Qingdao Kehai Bio11.4.1 Qingdao Kehai Bio Corporation Information11.4.2 Qingdao Kehai Bio Description and Business Overview11.4.3 Qingdao Kehai Bio Sales, Revenue and Gross Margin (2015-2020)11.4.4 Qingdao Kehai Bio Dibutyl Itaconate (CAS 2155-60-4) Products Offered11.4.5 Qingdao Kehai Bio Related Developments11.1 Zhejiang Guoguang Biochemistry Co.,Ltd11.1.1 Zhejiang Guoguang Biochemistry Co.,Ltd Corporation Information11.1.2 Zhejiang Guoguang Biochemistry Co.,Ltd Description and Business Overview11.1.3 Zhejiang Guoguang Biochemistry Co.,Ltd Sales, Revenue and Gross Margin (2015-2020)11.1.4 Zhejiang Guoguang Biochemistry Co.,Ltd Dibutyl Itaconate (CAS 2155-60-4) Products Offered11.1.5 Zhejiang Guoguang Biochemistry Co.,Ltd Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)12.1 Dibutyl Itaconate (CAS 2155-60-4) Market Estimates and Projections by Region12.1.1 Global Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast by Regions 2021-202612.1.2 Global Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast by Regions 2021-202612.2 North America Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast (2021-2026)12.2.1 North America: Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast (2021-2026)12.2.2 North America: Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast (2021-2026)12.2.3 North America: Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Country (2021-2026)12.3 Europe Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast (2021-2026)12.3.1 Europe: Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast (2021-2026)12.3.2 Europe: Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast (2021-2026)12.3.3 Europe: Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast (2021-2026)12.4.2 Asia Pacific: Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Region (2021-2026)12.5 Latin America Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast (2021-2026)12.5.1 Latin America: Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast (2021-2026)12.5.2 Latin America: Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast (2021-2026)12.5.3 Latin America: Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Dibutyl Itaconate (CAS 2155-60-4) Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Dibutyl Itaconate (CAS 2155-60-4) Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Dibutyl Itaconate (CAS 2155-60-4) Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Dibutyl Itaconate (CAS 2155-60-4) Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Dibutyl Itaconate (CAS 2155-60-4) Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

View original post here:
Dibutyl Itaconate (CAS 2155-60-4) Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 |...

Is ATA Risk Stratification Still a Reliable Predictor of Response in DTC? – Targeted Oncology

Oncologists who specialize in differentiated thyroid cancer (DTC) commonly use the American Thyroid Association (ATA) 2015 guidelines for risk stratification in patients. A real-world study assessed the performance of this system in patients with DTC and discovered that the system is reliable for predicting short-term outcomes.

The ATA risk stratification system is a reliable predictor of short-term outcomes in patients with DTC in real-world clinical settings characterized by appreciable treatment-center heterogeneity in terms of size, location, level of care, diagnostic resources, and local management strategies, Durante et al concluded, in the paper.

A report published inThyroid provided prospective 1-year data from 2000 patients who were treated in the real-world across 50 centers throughout Italy. Patients were found in the Italian Thyroid Cancer Observatory, an online database governed by the Thyroid Cancer Center of the Sapienza University of Rome. To be selected for the study, each patient record was required to have a histological diagnosis of DTC, papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), or poorly DTC and variants of these diseases. All patients were also required to have available information on treatment and pathological characteristics for investigators to determine their risk using the ATA risk stratification system. The third and final requirement was full information about each patients 1-year follow-up visit which was needed to estimate response to treatment.

Following the exclusion of 4610 cases from the database of 6867, the final cohort was compiled of 2071 patients from 40 centers. In 1109 patients (53.6%), the ATA risk of persistent and/or recurrent disease was classified as low, 796 patients (38.4%) were classified as intermediate risk, and 166 (8.0%) were classified as high risk.

Investigators led by Cosimo Durante, MD, found that in the overall population, 1576 patients (76.1%) had an excellent response, 376 (17.8%) had an indeterminate response, 33 (1.6%) had a biochemical incomplete responses, and structural incomplete responses were found in 86 patients (4.2%), which showed progressive increase with the baseline risk levels estimated as 1.5% in the low-risk patients, 5.7% in intermediate-risk patients, and 14.5% in high-risk patients. Prior treatment did impact responses to treatment at 1-year evaluation.

Of the patients with prior radioactive iodine remnant ablation, excellent responses were observed in 921 (77.3%), indeterminate responses were seen in 168 (14.1%), biochemical incomplete responses were observed in 33 (2.8%), and structural incomplete responses were observed in 69 patients (5.8%). Among those who had a total thyroidectomy, 655 (81.1%) had excellent responses, 137 (17%) had indeterminant responses, no patients had a biochemical incomplete response, and structural incomplete responses were seen in 15 patients (1.9%). Finally, among patients who had a thyroid lobectomy, 71 patients (97.3%) had an indeterminant response and 2 (2.7%) had a structural incomplete response. No patients in the thyroid lobectomy group had an excellent response or biochemical incomplete response.

A significant predictor of response to treatment was determined to be ATA risk class assigned at baseline, which was observed again at 1-year follow-up. There was no data for the low-risk group; however, the odds ratios (OR) for response to treatment in the intermediate-risk group was 4.67 (95% CI, 2.59-8.43;P<.0001). In the high-risk group, the OR was 16.48 (95% CI, 7.87-34.5;P<.0001). The results also showed a high probability of suboptimal response in patients classified as intermediate- to high-risk. Specifically, the OR that intermediate-risk patients would have a response to treatment was 1.68 (95% CI, 1.34-2.10;P<.0001). The OR that high-risk patients would respond was 3.23 (95% CI, 2.23-4.67;P<.0001).

Another assessment conducted during the study looked at how individual practice reporting impacted the performance of initial disease risk. The assessment included both academic and non-academic cancer centers. No impact was found.

Our findings demonstrate that the ATA risk stratification system for recurrent/persistent disease is indeed a reliable predictor at the 1-year follow-up evaluation, independent of treatment centers. This is true in spite of the fact that the likelihood of a less-than-excellent response varies across treatment centers, probably as a result of between-center differences in surgical volumes, case mixes, the availability of diagnostic tools, and/or other factors, wrote Durante et al.

Reference:

Durante C, Grani G, Zaelli MC, et al. Real-world performance of the American Thyroid Association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: A prospective multicenter study of 2000 patients. Thyroid. Published online July 1, 2020. doi: 10.1089/thy.2020.0272

See the article here:
Is ATA Risk Stratification Still a Reliable Predictor of Response in DTC? - Targeted Oncology

Global Automated Biochemical Analyzers Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -…

The research report on Automated Biochemical Analyzers market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The core objective of the Automated Biochemical Analyzers market report is to help organizations gain aa better understanding of this business sphere in terms of the key growth drivers, restraints, and opportunities influencing the market dynamics.

According to the report, the market is projected to expand with a CAGR of XX% over the review period 2020-2025.

In the midst of the lockdown due to the COVID-19 pandemic, several industries have been forced to halt their operations which has dealt a major blow to their revenues. Some of them are projected to face challenges even after the economy recovers.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/184545

Majority of businesses have realigned their priorities and revised their budget to ensure profitability in the forthcoming years. Our all-inclusive analysis of this industry suggests reliable strategies to help you draft a strong action plan for the future.

Further, the research report forecasts revenues and assesses the trends of each sub-market to identify the prospects of this market.

Major highlights of the Automated Biochemical Analyzers market report:

Automated Biochemical Analyzers Market segments covered in the report:

Regional segmentation: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

Product categories:

Market share of each product type based on their sales and revenue.

Application spectrum:

Competitive outlook:

Basic company details, manufacturing sites, and competitors of each company

Highlights of the Report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/184545

Original post:
Global Automated Biochemical Analyzers Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -...

More Than Words: Neurologic Societies Take Action On… : Neurology Today – LWW Journals

Article In Brief

The AAN, the American Neurological Association, and the American Epilepsy Society have responded to the call for action to address systemic racismwith initiatives that look specifically at what the field of neurology can do.

The American Academy of Neurology and other neurology organizations, like many other medical organizations, are grappling with the problem of systemic racism in health care and in their own organizations. And they have committed to taking sustained and specific actions to become genuinely anti-racist organizations.

Strong public statements are important, but we have to put action behind them, AAN President James C. Stevens, MD, FAAN, a specialist in sleep disorders medicine at the Fort Wayne Neurological Center in Indiana, told Neurology Today in a telephone interview.

Beginning in 2014, the AAN created its Diversity Leadership Program, and since then a variety of other task forces and leadership groups have worked on addressing issues of inequity, diversity, and inclusion within neurology and in the Academy.

In the fall of 2018, the Joint Coordinating Council on Equity, Diversity, Inclusion, and Disparities was established to ensure that recommendations from these groups, including the Diversity Leadership Program, Gender Disparities Task Force, and the Health Care Disparities Task Force, would be implemented across the entire organization.

But although a lot of work has been done, events of the past few months, including the heinous murder of George Floyd in Minneapolis, the home of AAN headquarters, have rightly focused people's attention on these injustices, and demonstrated that we must do much more, Dr. Stevens said.

So in early June, the Academy announced the creation of a special commission to recommend specific short-term and long-term action steps for the AAN to take toward becoming an anti-racist organization.

The AAN commits to enact sustained change for our members and patients, Dr. Stevens said in a statement released at the time. In this historic moment, we are resolved to pursue bold action beyond rhetoric and stand with the communities we serve to eliminate inequities that are antithetical to our values and the pursuit of our vision and mission.

These action steps will be presented to the AAN Board of Directors for review and approval by late summer.

What we need is not a knee-jerk, one-time response, but a sustained change in the way the organization approaches these issues, said Jeffrey McClean II, MD, FAAN, chair of the AAN Equity, Diversity, and Inclusion Joint Coordinating Council. That's why we created this special commission, to take a deep dive into the organization and the field and look comprehensively at what changes need to be made, both now and in the future, to sustainably move toward that ideal of being a fully inclusive and anti-racist organization.

The AAN Board charged the special commission to address two broad areas of focus: (1) the AAN itselfboth its structural composition and its programmatic workand changes necessary to achieve anti-racist goals; and (2) disparities in care, particularly within neurology and the neurosciences, and how the Academy can use its influence, resources, and expertise to mitigate and reduce these disparities.

The special commission includes chairs or vice chairs of all the major AAN committees, as well as chairs or editors-in-chief of all other major entities in the Academy, including its publications.

We have expertise about how the organization works and what it does from top to bottom, said Dr. McClean. We have combined that expertise and influence with a number of at-large members who have spent a lot of time working on issues related to equity, diversity, inclusion, anti-racism, and social justice.

Since early June, the special commission has conducted several large group meetings and small group breakouts (all virtual), and researched organizations in multiple different fields that have pursued organizational change to become anti-racistmost of them outside medicine.

We've used those lessons to inform us as we evaluate where the Academy is now, and what concrete steps to take toward becoming an anti-racist organization, Dr. McClean said.

Groundwork for the commission's work was also laid by a powerful presentation from members of the AAN's Emerging Leaders Program, who had been charged in October of 2019 with researching the question of how the Academy could become a fully inclusive society.

They were detailed in their recommendations and gave us a vision for the Academy moving forward, which really formed the foundation for the special commission as we looked into specific things to recommend to the Board of Directors, Dr. McClean said.

The special commission recently finalized its report for review, first by the Equity, Diversity and Inclusion Joint Coordinating Council and then by the AAN Board of Directors. The report and recommendations will be released publicly in the fall.

Even as the special commission conducted its work, further actions to pursue anti-racist goals were already underway at the AAN. In July, the AAN and Neurology Today hosted a webcast on health care disparities in the time of COVID-19, featuring Richard S. Isaacson, MD, FAAN, founder and director of the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center and Richard T. Benson, MD, PhD, director of the Office of Global Health and Health Disparities in the Division of Clinical Research at the National Institute of Neurologic Disorders and Stroke.

The broadcast focused on what AAN members can do to reduce disparities within their institution, how NIH and NINDS are working to address health care disparities across the country, and the importance of developing a diverse pipeline.

And on July 22, the AAN announced the establishment of a new Underrepresented in Neurology section, formed by leaders from the Society of Black Neurologists (SBN).

SBN was created about 18 months ago, explained Jimmy V. Berthaud, MD, MPH, an assistant professor in the department of neurology at the University of Michigan Medical School. At the time, there was really no overarching group for underrepresented minorities in the field of neurology to come together, so a small group of us decided to form a society on Facebook.

After SBN had reached more than 100 membersit now has more than 200Dr. Berthaud and other group leaders approached Dr. McClean about creating an official AAN Section. Less than a month after its founding in July 2020, the new section already had more than 50 members.

And in June, the SBN authored a powerful message on Neurology's blog site. Many of us have had the unfortunate experience of being called Ngger and other derogatory words by patients and colleagues. We are often mistaken for other health care workerscommonly janitors, maids, food service workers, and nurseseven while wearing our white coats and identification badges, wrote Dr. Berthaud and colleagues, including Ima Ebong, MD; Aaron Anderson, MD; Shaun Smart, MD; Uzo Ugochukwu, MD; and Andrew Spector, MD.

If not wearing our white coats, we are often not recognized by our colleagues in the hallways of our hospitals and clinics. We endure daily microaggressions regarding our physical appearances, including chosen styles of hair, and choice of attire. Yet we still pride ourselves to provide the best unbiased care possible to patients of all races, regardless of their perceptions of us as Black people.

The SBN and the section's immediate goals are to significantly increase their numbers and help to grow the pipeline of people of color coming into the field. Only about 2 to 3 percent of practicing neurologists are Black, and we want to increase those numbers, Dr. Berthaud told Neurology Today. For example, we recently held a Zoom forum for current medical students on how to apply for neurology residency positions, which had about 25 to 30 participants.

Like the AAN, the American Neurological Association (ANA), which represents academic neurologists and neuroscientists, is undergoing a similar self-examination on issues of race.

We first had to accept the fact that for the 143 years of our existence, we have been a relatively exclusionary society, says ANA President Justin C. McArthur, MBBS, FAAN, FANA, chair and professor of neurology at Johns Hopkins and founding director the of the Johns Hopkins/National Institute of Mental Health Research Center for Novel Therapeutics of HIV-associated Cognitive Disorders.

Until 15 years ago you could only get into the ANA by being nominated and selected. Those rules were changed with the intent of making the ANA more diverse, younger and more forward-looking, but in terms of social justice and equity, we know that the ANA has to take concrete steps to move us from where we were as an organization toward where we want to be.

The organization has created a new task force on Inclusion, Diversity, Equity, Anti-Racism and Social Justice (IDEAS) to address the diversity of its membership and representational leadership and fund health care disparities research. IDEAS has established an endowed lectureship in the name of Audrey Penn, MD, the first and only Black woman president of the ANA, who will help the organization select its first speaker for 2021.

The ANA has also developed a social justice Zoom series in partnership with Johns Hopkins, with sessions every Thursday from July into early September. We will have a series of speakers educating our members about systemic racism, implicit bias, and structural elements in our society that have led to health care disparities, said Dr. McArthur. Nearly 200 participants joined the first session, which featured Maya R. Cummings, PhD, former chair of the Maryland Democratic Party and the widow of Congressman Elijah Cummings (D-MD).

In October, the ANA will host a four-hour social justice symposium as part of its virtual Annual Meeting, which will include the presentation of a member survey on diversity and equity and a keynote address from Valencia Walker, MD, assistant dean for equity and diversity inclusion at the David Geffen School of Medicine at UCLA.

We are committed to making this a durable response, one that is self-sustaining, said Dr. McArthur. We have to be accountable for our outcomes and will use the social justice symposium at the ANA annual meeting to help us set those metrics. It's not a six-week feel-good campaign. We have been heavily influenced by some of our members of color who have courageously spoken up to candidly tell us that some of them do not feel welcome in our organization. That's a tough thing to say and we owe it to them to take change very seriously.

At the subspecialty society level, one organization that is planning significant, specific changes is the American Epilepsy Society (AES).

We have had an ongoing effort focused on diversity for the last several years, including a special task force on diversity in gender, and we had been working toward efforts on racial equity when the killings of George Floyd, Ahmaud Arbery and Breonna Taylor brought this issue to the forefront, said AES President William D. Gaillard, MD, FAAN, chief of the divisions of child neurology, epilepsy and neurophysiology at Children's National Hospital.

In response, we have created a Diversity, Equity and Inclusion Task Force, which will report to our board in September on goals and actions to embed in our new strategic plan.

Dr. Gaillard promises that the AES will embed within that strategic plan an ongoing process of addressing all levels of diversity, inclusion and equity, including the creation of a senior-level committee with ongoing responsibilities related to equity, diversity and anti-racism. The AES is also expanding on three existing efforts: These include prioritization of diversity, equity, and inclusion in the AES Fellows Program; an annual poster session at the AES Annual Meeting Better Patient Outcomes through Diversity; and governance that focuses on addressing diversity in appointments to serve on AES committees.

We view this as a long-term process, understanding that it requires constant effort, he said. This is one of those moments where I think it's possible to implement change because there is interest, enthusiasm, and a will to do things better.

While awaiting the release of the AAN special commission's recommendations in the fall, all neurologists can take action, starting with recommendations from the SBN's blog post.

Start with listening and most importantly believing when you hear what life is like for Black Americans, the SBN authors of the blog post wrote. The stories are not exaggerated. Take time to educate yourself with books like How to Be an Antiracist by Prof. Ibram X. Kendi, Black Man in a White Coat by Dr. Damon Tweedy, Medical Apartheid: The Dark History of Medical Experimentation on Black Americans from Colonial Times to the Present by Harriet Washington, or any of a number of similar resources. It is every physician's responsibility to learn what we can about a problem that is killing so many people.

Given the history of race and racism in our country, our society and in health care, the continuation of the effects of race and racism does not require that people actively perpetuate that system, said Dr. McClean. It has become self-perpetuating and it won't resolve on its own with time or even with increased diversity. It requires purposeful, proactive, and sustained action in order to reverse these things that have plagued our society for hundreds of years.

Read more:
More Than Words: Neurologic Societies Take Action On... : Neurology Today - LWW Journals

American Neurological Association Hosts First-Ever All-Virtual Annual Meeting – PRNewswire

MOUNT LAUREL, N.J., Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

SOURCE American Neurological Association

https://2020.myana.org

Continued here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PRNewswire

Studies by Pennsylvania’s AHN Neurologists Improve Understanding of Stroke Therapy Risks in Patients with Chronic Health Conditions – Cath Lab Digest

Pittsburgh, Pa (Sept. 2, 2020_ Intravenous thrombolysis may put stroke patients with chronic kidney disease (CKD) at a higher risk for intracranial bleeding and mortality, according to a recent study published in the journal Neurology by researchers at the Allegheny Health Network (AHN) Neuroscience Institute. The study, Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis, surveyed various studies published across different countries and assessed the association of CKD among more than 60,000 acute ischemic stroke patients undergoing IV thrombolytic therapy.

According to the CDC, stroke kills about 140,000 Americans each year, accounting for approximately one out of every 20 deaths. Nearly 90 percent of strokes are classified as acute ischemic strokes which take place when a blood clot or narrowed artery obstructs blood flow to the brain. Within minutes, the lack of oxygenated blood to the brain can cause a severe, permanent neurological injury, and even death.

Patients who suffer an acute ischemic stroke and arrive early to the hospital are often administered IV thrombolysis to dissolve dangerous clots in blood vessels, improve blood flow, and prevent damage to tissues and organs, said Konark Malhotra, MD, vascular neurologist at Allegheny General Hospital (AGH) and the AHN Neuroscience Institute, and principal investigator of the study. We wanted to better understand how this course of treatment with IV thrombolytic therapy may impact an already vulnerable population with a specific chronic condition like chronic kidney disease.

In the systematic review, Dr. Malhotra and his colleagues evaluated outcomes with special attention being paid to intracranial bleeding, three-month mortality and functional independence rates with regard to a patients mobility and ability to maintain high levels of self-sufficiency.

Across 20 independent studies that were analyzed, a significant correlation was determined to exist between CKD and worsened clinical outcomes most notably, a higher risk of intracranial bleeding and mortality.

The primary causation of worsened outcomes presents an opportunity for further research. A likely contributing factor is the high rate of comorbidities seen in the study population; for example, hypertension and diabetes are the leading causes of chronic kidney disorder, said Ashis Tayal, MD, neurologist and director of the AGH Stroke Center.

In addition to Dr. Malhotra and Dr. Tayal, other neurologists who contributed to the study include Aristeidis H. Katsanos, Nitin Goyal, Henrik Gensicke, Panayiotis D. Mitsias, Gian Marco De Marchis, Eivind Berge, Anne W. Alexandrov, Andrei V. Alexandrov and Georgios Tsivgoulis.

In anotherstudypublished earlier this year in the AHA Journal ofHypertension, Dr. Malhotras team provided additional insight on how clinical outcomes of acute ischemic stroke patients who undergo stroke thrombectomy procedures are impacted by elevated blood pressure levels.

Dr. Malhotra performed a systematic review and pooled results from 25 published studies involving 6,500 patients who underwent acute stroke thrombectomy. This study analyzed the association of blood pressure systolic and diastolic before, during or after acute stroke thrombectomy with various clinical outcomes. The authors found that higher blood pressure levels negatively affect stroke related outcomes such as intracranial bleeding, death and functional independence in daily living.

Studies such as those led by Dr. Malhotra and his team are essential to improving our understanding of chronic disease management and developing better therapeutic strategies that can make a life-changing difference for stroke patients, continued Dr. Tayal.

AHN was recently recognized by the American Stroke Association for its excellence in stroke care. In August, the Network announced six Network hospitals earned Gold Plus Elite and Silver Plus designations for its adherence to guideline-directed therapies and protocols which in turn improves patient outcomes and decreases stroke recurrence rates.

For more information on the AHN Neuroscience Institute, visit ahn.org.

Read the original here:
Studies by Pennsylvania's AHN Neurologists Improve Understanding of Stroke Therapy Risks in Patients with Chronic Health Conditions - Cath Lab Digest

Neurology care during the COVID-19 pandemic, an interventional neurologist’s perspective – Boca Newspaper

By: David DiPinoContributing Writer

Nils Mueller-Kronast, MD, an interventional neurologist with Palm Beach Neuroscience Institute (PBNI) continues to provide care during the COVID-19 Pandemic for a wide variety of neurological ailments and neurovascular diseases including stroke and brain aneurysm treatment.

At Dr. Nils Mueller-Kronasts PBNI office, safety protocols and guidelines continue to be in place and telehealth appointments are available. Those safety procedures include patient screening for fever and cough, following the Centers for Disease Control and Preventions (CDC) guidelines for social distancing by maintaining six-feet of distance between individuals in the waiting area and exam room and continuous wearing of masks by staff. In addition, Dr. Mueller-Kronast and his care staff wear gloves and masks during patient consultations, and the offices and waiting areas are routinely sanitized.

Healthcare providers take great efforts to ensure patient and staff safety during an office consultation by limiting the physical exam when appropriate, maintaining social distance during the consultation while wearing personal protective equipment (PPE) throughout the encounter. We also provide telehealth for new patients and follow-up appointments for added convenience and patient safety, said Dr. Mueller-Kronast.

Telehealth appointments may be appropriate when the neurological disease does not require a physical exam.

Bi-directional video and audio conferences provide an excellent patient experience without the inconvenience and perceived uncertainty of an in-person visit. If chosen for the correct patient and condition, there does not have to be a negative impact to not being in-person with the patient during the interaction and telehealth can allow us to determine the correct diagnosis and treatment, said Dr. Mueller-Kronast.

Additionally, Dr. Mueller-Kronast encourages going to the hospital for serious ailments and elective procedures.

In the hospital patients who are suspected of COVID-19, or are COVID-19 positive, are managed by separate staff in separate areas of the hospital. We also use telehealth to minimize staff exposure when feasible. All elective surgery patients are COVID-19 tested, said Dr. Mueller-Kronast.

As for the link between COVID-19 and stroke, Dr. Mueller-Kronast has seen rare occurrences.

Early during the first months of the epidemic, in certain hot spots, some hospitals reported a spike in embolic large vessel occlusion in COVID-19 positive patients. We have seen a few COVID-19 positive stroke patients with typically more severe disease but, as in many parts of the country, there appeared to be a hesitancy of patients to present to the emergency room, said Dr.Mueller-Kronast.

Lastly, Dr. Mueller-Kronast encourages our communities to continue making efforts in preventing the spread of the COVID-19 virus.

These are difficult times, and we have to take this disease seriously. Everyones efforts are required to minimize the risk of exposure for our most vulnerable members of society. I feel that wearing a mask to protect someone else from a potentially deadly disease is a small burden which I will happily shoulder, said Dr. Mueller-Kronast.

Dr. Nils Mueller-Kronast is an interventional neurologist with the Palm Beach Neuroscience Institute and is on-staff at Delray Medical Center in Delray Beach, St. Marys Medical Center in West Palm Beach and Florida Medical Center, a campus of North Shore located in Fort Lauderdale. In addition, Dr. Mueller-Kronast is the Regional Medical Director of Neurosciences for Tenet Healthcares Florida Region.

Dr. Mueller-Kronast specializes in stroke, vascular neurology office consultations, endovascular management of elective and ruptured aneurysm, endovascular management of vascular malformations (dural AV fistulas, arteriovenous malformations), intra-arterial stroke treatment, carotid, intracranial and other cerebrovascular stents. His Palm Beach Neuroscience Institutes offices are located in Boynton Beach, West Palm Beach and Sunrise, FL. Dr. Mueller-Kronasts Boynton Beach office is located at: 8756 Boynton Beach Blvd., Suite 2500, Boynton Beach, FL 33472. For more information visit: http://www.PBNI.com or call 561-499-7551.

Original post:
Neurology care during the COVID-19 pandemic, an interventional neurologist's perspective - Boca Newspaper

Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American Academy of Neurology -…

PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced the forthcoming presentation of efficacy and safety results from the pivotal MOXIe Part 2 study, a randomized, double-blind, placebo-controlled trial of omaveloxolone in Friedreichs ataxia.

The presentation will take place on September 24, 2020 as part of the 2020 Emerging Science presentations hosted by the American Academy of Neurology (AAN). David Lynch, M.D., Ph.D., will present the data. Dr. Lynch is an attending physician at the Childrens Hospital of Philadelphia (CHOP), professor of neurology at the Perelman School of Medicine at the University of Pennsylvania, and the principal investigator of the MOXIe study.

The AAN Science Committee selected this as one of 12 late-breaking abstracts, chosen from more than 150 abstracts submitted to the April 2020 AAN meeting, which was converted to a virtual meeting due to the COVID-19 pandemic. More information about the AAN presentation can be found at the AAN Emerging Science webpage: https://www.aan.com/education-and-research/research/2020-aan-science-highlights/.

Separately, Dr. Lynch will present the results of the MOXIe Part 2 study at the FARA 2020 Biomarker & Clinical Endpoint Meeting, also scheduled for September 24. More information about this meeting and Dr. Lynchs presentation there can be found at https://curefa.org/pdf/research/Agenda-Biomarker2020-draft.pdf.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reatas two most advanced clinical candidates, bardoxolone methyl ("bardoxolone") and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Contact:Reata Pharmaceuticals, Inc.(972) 865-2219http://reatapharma.com

Investors:Vinny JindalVice President, Investor Relations and Corporate Communications(469) 374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/

Forward-Looking Statements

This press release includes certain disclosures that contain forward-looking statements, including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as believes, will, may, aims, plans, model, and expects. Forward-looking statements are based on Reatas current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (ii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iii) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (iv) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (v) other factors set forth in Reatas filings with the U.S. Securities and Exchange Commission, including the detailed factors discussed under the caption Risk Factors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Here is the original post:
Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich's Ataxia at the American Academy of Neurology -...

Patient Groups Issue Guidelines for Ensuring Access to Care and Treatment for Rare Disease Patients, Citing Critical Needs and Gaps Further Exposed…

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Global Genes and the Child Neurology Foundation, as part of the Rare Access to Critical Therapies (ACT) collaboration, announced today the joint release of a report highlighting and supporting guiding principles of rare disease care and access which the groups assert are universally relevant to all patients with rare diseases. This report is based on multi-stakeholder workshops and rare disease landscape and literature evaluations led by ACT, which involves leading patient, provider, research, and industry organizations.

ACT was founded in late 2018 based on evidence of significant unmet need and care variability in patients with rare diseases, to ensure the rare disease patient perspective was fully considered as part of broader public discussions and policy formation that could impact and improve patient access to needed therapies, immediately and in the future.

Certain gaps in access to rare disease care, trials and treatment have widened, and others have been exposed during COVID-19. At the same time, weve seen an advancement in the pace and productivity of treatment discovery and drug development in response to a public health crisis, which offers hope, and perhaps a model for rare diseases. These developments and others on the policy front make the release of the report all the more timely.

The report, entitled Guiding Principles of Rare Disease Care and Patient Access, characterizes five fundamental expectations for rare disease patient care that all health stakeholders should acknowledge and act upon. Key areas where progress has and has not been made toward achieving these Guiding Principles are highlighted, as are areas where challenges and/or additional work remains to achieve the intention of each Guiding Principle.

The aggregate impact of rare diseases is as significant as diseases considered national priorities, though individual patient impact is often more profound. As such, our approaches to achieving each Guiding Principle must consider the efficiencies of broader solutions, while not missing the variability of individual patient needs. This report shows that there remains much work to do to strike the right balance for rare disease patients, despite breakthrough areas of progress, said Eric Faulkner, vice president, precision and transformative medicine at Evidera and executive director of the Genomics, Biotech and Emerging Technology Institute of the National Association of Managed Care Physicians, who served as the lead author for this publication.

Global Genes has been dedicated to supporting rare disease patients and their families since its inception, collectively bringing forward the community as one, increasing the voice and influence of those impacted every day, said Nicole Boice, co-founder of RARE-X and visionary for this effort, on behalf of Global Genes. We believe the Guiding Principles outlined in this report are a meaningful step forward to ensure that the patient perspective is front and center and included in all decisions related to access to treatments and care.

The five Guiding Principles that the multi-stakeholder leadership group believes are the right of every rare disease patient include:

Of the 7,000 rare diseases identified, 50% of them have a neurologic component and of those, 75% originate in childhood, stated Amy Brin, executive director/CEO of the Child Neurology Foundation. This robust intersection between rare disease and the child neurology community has provided a foundational alignment for our organization to co-lead this initiative with Global Genes since 2018, and calls for patients to be seen and heard first within all conversations about access to critical therapies.

We hope readers find this manuscript to be enlightening in the clear identification of the core principles that are due all patients, while also highlighting key areas where stakeholders must come together to collectively address and solve for desperately needed care and access solutions, said Timothy M. Miller, vice president and global therapeutic area head, leader of the Rare Disease and Pediatrics Center of Excellence at Evidera/PPD and a co-author.

The full report, jointly presented by Global Genes and the Child Neurology Foundation, is available to download here: https://globalgenes.org/resources/guiding-principles-of-rare-disease-care-and-patient-access/.

About Global Genes

Global Genes is a 501(c)(3) nonprofit organization that connects, empowers, and inspires the rare disease community, with the ultimate goal of eliminating the burdens of rare disease for patients and families everywhere. We provide hope for the more than 400 million people affected by rare disease around the globe. We fulfill our mission by helping patients find and build communities, gain access to information and resources, connect to researchers, clinicians, industry, government and other stakeholders, share data and experiences, and stand up, stand out, and become effective advocates on their own behalf. If you or someone you love have a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit the resource hub at http://www.Globalgenes.org.

About the Child Neurology Foundation

The Child Neurology Foundation serves as a collaborative center of education and support for children living with neurologic conditions and their families. We connect partners from all areas of the child neurology community so that those navigating the journey of disease diagnosis, management, and care have ongoing support from those dedicated to treatments and cures. Our expanding network of patients and caregivers, advocates, partners, researchers, and physicians is committed to helping one another along the path that leads to the best quality of care and the highest quality of life for every child. For more information, check out CNFs website!

The rest is here:
Patient Groups Issue Guidelines for Ensuring Access to Care and Treatment for Rare Disease Patients, Citing Critical Needs and Gaps Further Exposed...

Existing Class of Drugs May Improve Neurological Function in Patients with Rare, Aggressive Genetic Disorder – Newswise

Philadelphia, September 3, 2020 New findings from Childrens Hospital of Philadelphia (CHOP) show that some patients with a rare and aggressive form of leukodystrophy may benefit from receiving treatment with a class of targeted therapy drugs that could improve their neurological function. A correspondence about these findings was published today in the New England Journal of Medicine.

Aicardi-Goutires syndrome (AGS) is a rare genetic disorder and type of leukodystrophy that affects the brain and immune system. In patients with AGS, the bodys immune system turns on itself in a destructive way, targeting the brains white matter, causing most children with the disorder to experience mild to severe intellectual or physical impairments. Most children with AGS are unable to walk or talk and have multisystemic complications, including skin inflammation.

Prior studies have linked the activation of interferons signaling proteins that respond to various immune disruptions to exacerbated symptoms in AGS. Researchers at CHOP wanted to explore whether a class of small molecule inhibitor drugs called janus kinase (JAK) inhibitors could be used to block interferon activation in a way that helped these patients.

Because treatment options for AGS are limited and the symptoms that these patients experience are so severe, there is a need to explore a wide variety of options, said senior author Adeline Vanderver, MD, an attending physician in the Division of Neurology, Program Director of the Leukodystrophy Center, and Jacob A. Kamens Endowed Chair in Neurologic Disorders and Translational Neurotherapeutics at CHOP.

The study was conducted at CHOP with 35 international patients with genetically confirmed AGS. These patients received baricitinib, an oral JAK1 and JAK2 inhibitor, with doses based on each patients renal function, age and symptoms. Patients had their developmental histories evaluated from the onset of the disease to the end of the study, which ranged from 7.4 months to 41.5 months. The study team analyzed a variety of developmental milestones, including head control, sitting, rolling, smiling, babbling, and the use of single words and word combinations.

Before the patients in this study received treatment, 26 of the 35 had stable or declining neurologic function, and 9 of the 35 patients gained one or two of these developmental skills after disease onset. However, during the study, 20 patients met new milestones, and 12 patients gained between two to seven new skills. The improvements were typically observed within three months into the study and persisted. Children who received higher doses of the therapy appeared to achieve more of these milestones.

Some of the AGS patients who received baricitinib were at risk for developing thrombocytosis, leukopenia, and infection and therefore should be monitored closely while taking the drug.

Measuring neurologic improvements in these patients is a complex process, but the results of this study are encouraging, especially because we observed improvements even in patients with severe and long-standing disease, Vanderver said.

Eli Lilly provided the medication for the study and performed the safety laboratory tests. This work was supported by grants NINDS U01 NS106845 and NICHD U01HD082806 and the State of Pennsylvania, Commonwealth Universal Research Enhancement Program, the J.A. Kamens Chair in Translational Neurotherapeutics from CHOP; grant KL2TR001879 from the National Center for Advancing Translational Sciences of the NIH, K23NS114113 the National Institute of Neurological Disorders and Stroke of the NIH, and K08-HL140129 from the Parker B. Francis Foundation; and funding from the Department of Pediatrics at CHOP.

Vanderver et al, Janus Kinase Inhibition in the AicardiGoutires Syndrome. N Engl J Med, online September 3, 2020. DOI: 10.1056/NEJMc2001362.

About Childrens Hospital of Philadelphia: Childrens Hospital of Philadelphia was founded in 1855 as the nations first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Childrens Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Link:
Existing Class of Drugs May Improve Neurological Function in Patients with Rare, Aggressive Genetic Disorder - Newswise

No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter…

The pathophysiology of pain in neuropathy is complex and may be linked to sensory phenotypes. Quantitative sensory testing, a standardized method to evaluate sensory profiles in response to defined stimuli, assesses functional integrity of small and large nerve fiber afferents and central somatosensory pathways. It has revealed detailed insights into mechanisms of neuropathy, yet, it remains unclear if pain directly affects sensory profiles. The main objective of this study was to investigate sensory profiles in patients with various neuropathic conditions, including polyneuropathy, mononeuropathy, and lesions to the central nervous system, in relation to self-reported presence or absence of pain and pain sensitivity using the Pain Sensitivity Questionnaire.A total of 443 patients (332 painful and 111 painless) and 112 healthy participants were investigated. Overall, loss of sensation was equally prevalent in patients with and without spontaneous pain. Pain thresholds were equally lowered in both patient groups, demonstrating that hyperalgesia and allodynia is just as present in patients not reporting any pain. Remarkably, this was similar for dynamic mechanical allodynia. Hypoalgesia was more pronounced in painful polyneuropathy whereas hyperalgesia was more frequent in painful mononeuropathy (compared to painless conditions). Self-reported pain sensitivity was significantly higher in painful than in painless neuropathic conditions.Our results reveal the presence of hyperalgesia and allodynia in patients with central and peripheral lesions of the somatosensory system not reporting spontaneous pain. This shows that symptoms and signs of hypersensitivity may not necessarily coincide, and that painful and painless neuropathic conditions may mechanistically blend into one another.

PubMed

View original post here:
No pain, still gain (of function): the relation between sensory profiles and the presence or absence of self-reported pain in a large multicenter...

Peloton Introduces Its First-Ever Health And Wellness Advisory Council – PRNewswire

NEW YORK, Sept. 1, 2020 /PRNewswire/ -- Peloton (NASDAQ: PTON), the world's largest interactive fitness platform, today announced the formation of the Peloton Health and Wellness Advisory Council, which will work closely with the company as it continues to look at how it can positively impact the physical, mental and emotional wellbeing of its community of Members from around the world. Peloton will collaborate with the council, which includes five renowned doctors, researchers and other medical professionals from the fields of cardiovascular medicine, cardiopulmonary exercise, neurology and neuroscience, and draw on their knowledge and expertise to help inform product and content development, community-focused and social impact initiatives, research projects and more.

"We constantly hear from our Members that Peloton has not only profoundly impacted their physical, mental and emotional health, but has also helped them cope with issues ranging from neurodegenerative disease or cancer, to PTSD or post-partum depression," said William Lynch, president, Peloton. "With the addition of this esteemed Health and Wellness Advisory Council, which includes some of the best minds in medicine, we can leverage scientific research and medical expertise to help us better serve our community through our content, products and platform."

The Peloton Health and Wellness Advisory Council includes the following experts:

Cardiovascular MedicineSuzanne Steinbaum, MD:Dr. Suzanne Steinbaum is an attending cardiologist, specializing in prevention. She has recently opened a private practice in New York City, at the Juhi-Ash integrative health center encompassing heart health, wellness and prevention, as well as the effects of stress and inflammation on heart health. She is the founder and President of SRSHeart, a personalized lifestyle management program using anatomy, physiology, functional data, genetics and metabolism, along with technology to reach ultimate cardiovascular health. She has been the Director of Women's Cardiovascular Prevention, Health and Wellness at Mt. Sinai Heart in New York City, after being the Director of Women's Heart Health at Northwell Lenox Hill. Dr. Steinbaum is a Fellow of the American College of Cardiology and the American Heart Association. She is a National Spokesperson for the Go Red for Women campaign and chairperson of the Go Red for Women in New York City. She is on the New York City Board of the American Heart Association and on the Scientific Advisory Board of the Women's Heart Alliance.

NeurologyRichard S. Isaacson, MD:Richard S. Isaacson, M.D. is a Neurologist, clinician and researcher who specializes in Alzheimer's prevention and treatment. He previously served as Associate Professor of Clinical Neurology, Vice Chair of Education, and Education Director of the McKnight Brain Institute in the Department of Neurology at the University of Miami (UM) Miller School of Medicine. Prior to joining UM, he served as Associate Medical Director of the Wien Center for Alzheimer's disease and Memory Disorders at Mount Sinai. Dr. Isaacson specializes in Alzheimer's disease (AD) risk reduction and treatment, mild cognitive impairment due to AD and preclinical AD. His clinical research has shown that individualized clinical management of patients at risk for AD dementia is an important strategy for optimizing cognitive function and reducing risk of dementia. He has also published novel methods on using a precision medicine approach in real-world clinical practice. He has also led the development of Alzheimer's Universe (AlzU.org) a vast online education research portal on AD with results published in the Journal of the Prevention of Alzheimer's disease, Journal of Communication in Healthcare, Alzheimer's & Dementia: Translational Research & Clinical Interventions, and Neurology. With a robust clinical practice and broad background in computer science, m-Health, biotechnology and web-development, Dr. Isaacson is committed to using technology and lifestyle interventions (such as physical exercise and nutrition) to optimize patient care, AD risk assessment and early intervention.

Vernon Williams, MD:Vernon Williams, MD is the Founding Director of the Center for Sports Neurology and Pain Medicine at Cedars-Sinai Kerlan-Jobe Institute in Los Angeles, CA. Dr. Williams is a former Commissioner for the California State Athletic Commission and current Chair of Neurological Health for the Commission's Medical Advisory Committee, as well as a former two-term Chair of the American Academy of Neurology Sports Neurology Section. He serves as a neurological medical consultant to local professional sports organizations such as the Los Angeles Rams, Los Angeles Dodgers, Los Angeles Lakers, Los Angeles Kings and Los Angeles Sparks. He also assists local colleges and numerous high school and youth sports/club athletic teams in this capacity. Dr. Williams is a board-certified clinical neurologist with very specialized areas of subspecialty: Sports Neurology and Pain Medicine. He is actively engaged in researching and developing innovative and effective treatments and technologies that help people recognize symptoms of a neurological injury sooner so that the work of treating them can happen faster, and with less potential for permanent damage. He passionately advocates for optimization of Neurological Health across the lifespan for his patients and peak performance clients.

Cardiopulmonary ExerciseAimee M. Layton, PhD:Aimee Layton, PhD is an Assistant Professor of Applied Physiology in Pediatrics in the Division of Pediatric Cardiology and the Director of the Pediatric Cardiopulmonary Exercise Laboratory at Columbia University Medical Center / New York Presbyterian Hospital. Dr. Layton recently joined the pediatric cardiology team after being director of the adult pulmonary exercise laboratory for a decade. This cross discipline experience provides Dr. Layton with knowledge of both how the lungs and the heart respond to exercise and the role of disease and sports in both adults and kids. Dr. Layton's prior research investigated respiratory biomechanics, with publications in both diseased and healthy populations. Her new research focuses on bridging the gap between the lab and the home, in hopes of impacting kids' behavior and relationship with exercise. Dr. Layton is a respected expert in clinical exercise physiology and has lectured internationally on the topic. Beyond her research, Dr. Layton has been performing exercise testing and counseling for both patients with lung disease and patients with heart disease. She plays an important role as one of the lead exercise physiologists for Columbia University Medical Center in testing, exercise counseling and research.

NeuroscienceJay Alberts, PhD:As a Cleveland Clinic Scientist, Ph.D., Jay Alberts' research is aimed at understanding the structure-function relationships within the central nervous system and evaluating the impact of behavioral and surgical interventions to improve motor and non-motor function in Parkinson's disease, stroke, Alzheimer's and other neurological populations. Human studies are currently ongoing to address these basic and translational research questions. Dr. Alberts is developing and validating new methods of using exercise and augmented and virtual reality to engage patient populations remotely. He is currently leading two multi-site clinical trials investigating the role of exercise in slowing the progression of Parkinson's disease. Dr. Alberts has led multiple successful technology initiatives aimed at better understanding patient symptoms and communicating these symptoms to providers. He is currently building AR and VR applications as prescriptive digital therapeutic systems for neurological patients. To date, Dr. Alberts has written 100 peer reviewed articles, has had uninterrupted extramural funding since 1999 and holds 10 patents.

For more information about Peloton or the Peloton Health and Wellness Advisory Council, please visit http://www.blog.onepeloton.com.

About PelotonPeloton is the largest interactive fitness platform in the world with a loyal community of more than 2.6 million Members. The company pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its Members anytime, anywhere. Peloton makes fitness entertaining, approachable, effective, and convenient, while fostering social connections that encourage its Members to be the best versions of themselves. An innovator at the nexus of fitness, technology, and media, Peloton has reinvented the fitness industry by developing a first-of-its-kind subscription platform that seamlessly combines the best equipment, proprietary networked software, and world-class streaming digital fitness and wellness content, creating a product that its Members love. The brand's immersive content is accessible through the Peloton Bike, Peloton Tread, and Peloton App, which allows access to a full slate of fitness classes across disciplines, on any iOS or Android device, Apple TV, Fire TV, Roku TVs, and Chromecast and Android TV. Founded in 2012 and headquartered in New York City, Peloton has a growing number of retail showrooms across the US, UK, Canada and Germany. For more information, visit http://www.onepeloton.com.

SOURCE Peloton

http://www.pelotoncycle.com

Go here to read the rest:
Peloton Introduces Its First-Ever Health And Wellness Advisory Council - PRNewswire

Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms? – Pharmacy Times

Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms?

She has been in the hospital for 5 days and during that time the doctors did all the expensive tests looking for blood clots, ischemia,inflammation, infection, and malignancies in the brain andnervoussystem. But they find nothing. The doctor says he is at a loss to what is causing JKs symptoms.

As the pharmacist for the team, you review JKs medications, and the dosages according to her weight of 86 kg and renal function of eCrCl of 45 ml/min.

Mystery: Which is the medication dose you want to lower and why?

Solution: Gabapentin. JK had a decline in renal function, as verified by changes in SrCr, and that caused gabapentin to accumulate to toxic levels. JK will need a new lower dose to stay symptom-free.Renal disease for gabapentin are as follows: eCrCl 30-59ml/min 700mg bid, eCrCl 15-29 ml/min 700mg qd, eCrCl <15 ml/min 300mg/day.1

Drug levels for gabapentin can easily accumulate and reach toxic levels when renal function declines or when the recommended dosage is exceeded. I believe this is an under recognized problem that can be easily addressed by pharmacists.2

REFERENCES

Read more:
Monday Pharmaceutical Mystery: What Medication May Be Causing Neurological Symptoms? - Pharmacy Times

Interventional Neurology Device Market Outlook, Recent Trends and Growth Forecast 2020-2025 – The Research Process

Latest update on Interventional Neurology Device Market Analysis report published with an extensive market research, Interventional Neurology Device market growth analysis and Projection by 2025. this report is highly predictive as it holds the over all market analysis of topmost companies into the Interventional Neurology Device industry. With the classified Interventional Neurology Device market research based on various growing regions this report provide leading players portfolio along with sales, growth, market share and so on.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/300

A Interventional Neurology Device market analysis report covers historical data of recent five years along with a forecast from to 2025 based on revenue. This report includes drivers and restraints of the global Interventional Neurology Device market along with the impact they have on the demand over the forecast period. Also, the report provides company Interventional Neurology Device market share analysis to give a broader overview of the key players in the market.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/300

The report evaluates several factors determining the Interventional Neurology Device market expansion as well as the volume of the whole Market. The report states the aggressive vendor scenery of the market together with the profiles of some of the leading Interventional Neurology Device market players.

Some of the Major Interventional Neurology Device Market Players Are:

The report provides data taking into attention the latest advancements in the global Interventional Neurology Device Market while appraising the impact in the Interventional Neurology Device market of the most important players in the near future.

Interventional Neurology Device Market Outlook by Applications:

Treatment of Cerebral Aneurysms, Treatment of Cerebral Vasospasm and Vertebroplasty

Interventional Neurology Device Market Statistics by Types:

Embolization & coiling and Neurothrombectomy Devices

Objective of Studies of Interventional Neurology Device Market:

The Interventional Neurology Device research report provides answers to the following key questions:

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/300

View post:
Interventional Neurology Device Market Outlook, Recent Trends and Growth Forecast 2020-2025 - The Research Process

Social Neurology Software Market Research Methodology Focuses On Exploring Major Factors Influencing the Industry Development 2025 – Galus Australis

The Social Neurology Software Market which explains the future and present measurements of the market as for the patterns in play. The principle reason for the investigation is to legitimize the occurrences in the market by giving reader helpful and suitable bits of knowledge on the particulars of the market for the future extent of development and accessible prospects at the current situation with the market. The statistical surveying production additionally manages features, for example, drivers, restrictions, and prospects to measure the result of the market amid the conjecture time frame specified in the report.

Top Key Vendors: Epic,Brainlab,healthfusion,Athenahealth,Practice Fusion,Nextgen,Bizmatics,Greenway Health,Allscripts,Kareo,Advanced Data Systems,NueMD

Get Sample Copy @ https://www.itintelligencemarkets.com/request_sample.php?id=937

An analysis of the major trends in the global Social Neurology Software Market in the past years, which have significantly contributed in shaping the current state of the market, and the important trends of the current times is also included in the report, allowing the reader to formulate winning strategies. The data has been gathered with the help of a number of primary and secondary research methodologies and narrowed-down with the help of industry-best analytical methods.

Segmenting the global Social Neurology Software Market on several fronts, the research report examines the strengths and weaknesses of each category and sub-category in the operating environments. The report also analyses the impact of several internal and external forces such as consumer preferences, government regulations, laws and policies, technological developments, and economic environment for each segment.

Get Reasonable Discount on This Premium Report @

https://www.itintelligencemarkets.com/ask_for_discount.php?id=937

The regions North America, Global, Asia Pacific, Middle East & Africa and Latin America have been studied in depth to gain better market penetration and assure exact analysis. Top manufacturers have been given prime importance to make sure their strategies are understood and their position in this particular market can be elucidated.

The conclusions of this report illustrate the potential of the global Social Neurology Software Market in terms of investment potential in various segments of the market and illustrate the feasibility of explaining the feasibility of a new project to be successful in the near future. The core segmentation of the global market is based on product types, SMEs and large corporations. The report also collects data for each major player in the market based on current company profiles, gross margins, sales prices, sales revenue, sales volume, photos, product specifications and up-to-date contact information.

If You Have Any Query, Ask Our Experts @ https://www.itintelligencemarkets.com/enquiry_before_buying.php?id=937

Key Points Covered in TOC:

Global Social Neurology Software Market Research Report

Chapter 1 Global Social Neurology Software Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Productions, Revenue (Value) by Region

Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions

Chapter 6 Global Productions, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Social Neurology Software Market Forecast.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, or Asia.

About Us:

At IT Intelligence Markets, we model all our work on our core philosophy that believes in customer satisfaction. We serve a global clientele by supplying market intelligence research reports after conducting exhaustive research. Our reports are replete with productive insights & recent market dynamics as the healthcare industry is constantly undergoing changes like ever-changing consumer preferences, supply channels and latest technologies. Our market research analysts not only investigate the market for drivers, restraints & challenges but also gauge the overall progress of the market by comparing chief market players. Our report forms a crucial piece of intelligence using which our clients can unleash their potential & tap their capacity to harness the correct technologies & surpass their competitors.

Contact us:

Erika Thomas

76 AT US 19 & HWY

129 Murphy Highway,

Blairsville, GA, USA

Email:[emailprotected]

Phone: +1 888-312-3102

View post:
Social Neurology Software Market Research Methodology Focuses On Exploring Major Factors Influencing the Industry Development 2025 - Galus Australis